ten Bosch John Roderick sold $142K of BLLN

ten Bosch John Roderick (SVP of Laboratory Operations) sold 1,417 shares of BillionToOne, Inc. (BLLN) at $100.00 ($0.14M total) on 2026-08-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ten Bosch John Roderick
Published Aug 28, 2026, 12:19 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 28, 2026, 12:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Neutral
high confidence
Mentioned
$BLLN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNNeutralLow
01

Why it matters

Routine insider sale with limited market effect

02

Market read

Low relevance; typical insider transaction

03

What to watch

Potential future sales under the 10b5‑1 plan

Relevance 3/10Novelty 4/10Timing: filed 2026-08-27

Background

Form 4 filing discloses insider transactions to the SEC

Company-level read

Ticker impact

$BLLNNeutralHigh confidence
Context

Officer sold 1,417 shares for $141,700 via 10b5-1 plan on 2026-08-25

Expected impact

little to no movement

Evidence & confidence

Sale size is small relative to market cap and follows a pre‑arranged plan

Market effects

none

none

none

Counterpoint

Insider sale could signal concerns, but size is trivial

Key entities

  • BillionToOne, Inc.

    Issuer of the shares sold

  • ten Bosch John Roderick

    SVP of Laboratory Operations, insider seller

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

$BLLNMed

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.